Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

AGM Statement

8 Sep 2011 07:00

RNS Number : 8405N
Immunodiagnostic Systems Hldgs PLC
08 September 2011
 



 

 

Immunodiagnostic Systems Holdings plc

("IDS" or "the Company")

 

AGM Statement

 

Immunodiagnostic Systems Holdings plc (AIM: IDH), a leading producer of specialist diagnostic testing kits for the clinical and research markets, will hold its Annual General Meeting today at 3.00pm at the offices of Brewin Dolphin Limited at 12 Smithfield Street, London EC1A 9BD.

 

At the meeting Chairman, David Evans, will make the following statement to shareholders:

 

"Revenues to 31 August are £22.6m compared with £18.4m for the comparative period in 2010. We have seen continued growth in our IDS-iSYS revenues which have grown £4.4m over the comparative period. As of 31 August 299 instruments have been sold or placed an increase of 58 systems since the year end and we anticipate a further 15 instruments being placed or sold in September. Average revenue per instrument is £88k compared to £72k in August 2010.

 

Our revenues are traditionally weighted to the second-half of the year and we believe this year that the trend ratio will be higher this financial year reflecting both a seasonally quieter July and August and also higher anticipated reagent / instrument sales pull-through and the anticipated continued resilience of manual product sales in the second-half.

 

The process of transition in terms of the Board has continued since the year end. We have added Roland Sackers, the CFO of QIAGEN N.V. and at the end of this meeting Anthony Martin, who has a long-established track record in the diagnostics and life sciences space, will succeed me as Chairman.

We remain active in examining the potential for licensing-out our automated IDS-iSYS platform into other disease areas not served by the Company and which can help drive value. We have ongoing discussions in autoimmune disease and in coagulation testing outside of Europe and we will keep you updated as discussions progress.

 

Finally we continue to seek acquisitions where we believe we can either add value to our existing franchise in bone and mineral disease or where we can validly exploit the IDS-iSYS asset base.

 

A more detailed trading update will be given week commencing 3rd October."

 

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel: 0191 519 0660

Ian Cookson, Chief Executive Officer

Paul Hailes, Finance Director

 

 

 

Brewin Dolphin

Tel: 0845 213 4930

Matt Davis

Sean Wyndham-Quin

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

paul.mcmanus@walbrookpr.com

Fiona Henson

fiona.henson@walbrookpr.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMSSAFWWFFSEFU
Date   Source Headline
6th Dec 20182:59 pmRNSDirector/PDMR Shareholding
23rd Nov 20185:04 pmRNSHalf-year Report
19th Oct 20185:18 pmRNSH1 Trading Update
4th Sep 20188:00 amRNSCompletion of Share Buyback
30th Aug 20187:00 amRNSProposed Share Buyback
7th Aug 20185:48 pmRNSTransaction in Own Shares
7th Aug 20187:00 amRNSTransaction in Own Shares
1st Aug 20186:06 pmRNSTransaction in Own Shares
31st Jul 20186:02 pmRNSTransaction in Own Shares
26th Jul 20185:59 pmRNSResult of AGM
26th Jul 20187:00 amRNSAGM Statement
11th Jul 20185:33 pmRNSTransaction in Own Shares
20th Jun 20187:05 amRNSPublication of Annual Report and Accounts
20th Jun 20187:00 amRNSFinal Results
13th Jun 20185:07 pmRNSTransaction in Own Shares
6th Jun 20188:04 amRNSTransaction in Own Shares
20th Apr 20184:35 pmRNSTrading Statement
12th Apr 20185:21 pmRNSTransaction in Own Shares
6th Apr 20185:47 pmRNSTransaction in Own Shares
5th Apr 20182:16 pmRNSTransaction in Own Shares
29th Mar 20186:25 pmRNSDirector/PDMR Shareholding
29th Mar 20186:21 pmRNSDirector/PDMR Shareholding
29th Mar 20181:32 pmRNSLaunch of two new automated assays
29th Mar 20187:00 amRNSTransaction in Own Shares
26th Mar 20185:08 pmRNSTransaction in Own Shares
23rd Mar 20183:59 pmRNSTransaction in Own Shares
21st Mar 20185:50 pmRNSDirectorate Change
21st Mar 20181:08 pmRNSDirector/PDMR Shareholding
1st Mar 20184:50 pmRNSTransaction in Own Shares
22nd Feb 20185:02 pmRNSTransaction in Own Shares
21st Feb 20185:30 pmRNSTransaction in Own Shares
15th Feb 20185:20 pmRNSTransaction in Own Shares
13th Feb 201812:13 pmRNSTransaction in Own Shares
12th Feb 20181:22 pmRNSTransaction in Own Shares
6th Feb 20184:49 pmRNSTransaction in Own Shares
5th Feb 20183:19 pmRNSTransaction in Own Shares
2nd Feb 20182:47 pmRNSTransaction in Own Shares
24th Jan 20181:21 pmRNSTransaction in Own Shares
16th Jan 20187:00 amRNSPartnership Agreement with Technogenetics
15th Jan 20184:45 pmRNSTransaction in Own Shares
27th Dec 20175:16 pmRNSTransaction in Own Shares
24th Nov 20174:30 pmRNSHalf-year Report
23rd Nov 20175:15 pmRNSTransaction in Own Shares
14th Nov 201712:06 pmRNSTransaction in Own Shares
13th Nov 20175:37 pmRNSTransaction in Own Shares
2nd Nov 20176:05 pmRNSTransaction in Own Shares
1st Nov 20174:29 pmRNSAdditional Listing
1st Nov 20174:05 pmRNSTransaction in Own Shares
31st Oct 20176:22 pmRNSDirectorate Change
31st Oct 20176:03 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.